Amalgamated Bank’s MapLight Therapeutics MPLT Stock Holding History

Amalgamated Bank’s Portfolio MPLT Stock Details MPLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-530	Closed	-$9K	–	2983
2025 Q4	$9K	Buy	+530	New	+$8.88K	﹤0.01%	2495

Other funds holding MPLT

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Amalgamated Bank's MPLT Position: Q1 2026 in Review

Amalgamated Bank sold out of MapLight Therapeutics (MPLT) in Q1 2026, closing a stake of 530 shares — an estimated $9K sold.

Amalgamated Bank first reported a position in MPLT in Q4 2025 and held it in 1 quarter. The position peaked at $9K in Q4 2025. 81 funds tracked by Wall St. Rank hold MPLT as of Q1 2026.

Amalgamated Bank reported no remaining MapLight Therapeutics position as of Q1 2026 after selling out during the quarter.
Amalgamated Bank sold 530 MapLight Therapeutics shares in Q1 2026, an estimated $9K.
Amalgamated Bank first reported a position in MapLight Therapeutics in Q4 2025 and held it in 1 quarter.
Amalgamated Bank's MapLight Therapeutics position peaked at $9K in Q4 2025.
81 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.